Allergy Therapeutics plc (LON:AGY)’s share price rose 0.4% during mid-day trading on Tuesday . The company traded as high as GBX 11.80 ($0.15) and last traded at GBX 11.80 ($0.15), approximately 13,000 shares traded hands during mid-day trading. A decline of 92% from the average daily volume of 167,682 shares. The stock had previously closed at GBX 11.75 ($0.15).
Separately, FinnCap reissued a “corporate” rating on shares of Allergy Therapeutics in a research note on Thursday, July 11th.
The business’s fifty day simple moving average is GBX 13.69. The stock has a market cap of $74.75 million and a P/E ratio of -23.50. The company has a debt-to-equity ratio of 6.20, a quick ratio of 3.08 and a current ratio of 3.74.
Allergy Therapeutics Company Profile (LON:AGY)
Allergy Therapeutics plc engages in the research and development of allergy treatments. It sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees. The company's products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, and Venomil.
Featured Story: How Do You Calculate Return on Investment (ROI)?
Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.